Monoclonal antibody therapy for B cell non-Hodgkin's lymphomas: Emerging concepts of a tumour-targeted strategy

European Journal of Cancer

Volumn 35, Issue 4, 1999, Pages 549-557

  Buske, C ^a,b   Feuring Buske, M ^a   Unterhalt, M ^a   Hiddemann, W ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Anti idiotype antibody; Antibody therapy; Chimeric antibody; Immunotoxin; Malignant lymphoma; Radioimmunoconjugate

Indexed keywords

ANTIBODY CONJUGATE; ANTIIDIOTYPIC ANTIBODY; BACTERIAL TOXIN; CHIMERIC ANTIBODY; CYCLOPHOSPHAMIDE; DIPHTHERIA TOXIN; DOXORUBICIN; IMMUNOTOXIN; INTERLEUKIN 2; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY I 131; MONOCLONAL ANTIBODY IDEC CD B8; PREDNISONE; RADIOISOTOPE; RICIN; UNCLASSIFIED DRUG; VINCRISTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APHASIA; B CELL LYMPHOMA; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CAPILLARY LEAK SYNDROME; CLINICAL TRIAL; DRUG TARGETING; HUMAN; LUNG EDEMA; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOLOGY; REVIEW; RHABDOMYOLYSIS;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CHIMERA; FORECASTING; HUMANS; IMMUNOTOXINS; LYMPHOMA, B-CELL;

EID: 0033119071     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(98)00420-1     Document Type: Review

References (99)

1. Devesa S.S., Blot W.J., Stone B.J., Miller B.A., Tarone R.E., Fraumeni J.F. Jr. Recent cancer trends in the United States. J. Natl. Cancer Inst. 87:1995;175-182.
2. DeVesa S.S., Fears T. Non-Hodgkin's lymphoma time trends. United States and international data. Cancer Res. 52:(Suppl. 19):1992;5432-5440.
3. Coleman MP, Esteve J, Damiecki P, Arslan A, Renard H. Non-Hodgkin's lymphoma (ICD9 200, 202) in trends in cancer incidence and mortality, 1993. IARC Publication no. 121, Lyon, 1993, 641-653.
4. Parker S. Cancer statistics. CA Cancer Journal for Clinicians. 65:1996;5-27.
5. Harris N.L., Jaffe E.S., Stein H., et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 84:1994;1361-1392.
6. Hiddemann W., Longo D.L., Coiffier B., et al. Lymphoma classification - the gap between biology and clinical management is closing. Blood. 88:1996;4085-4089.
7. Longo D.L., Glatstein E., Duffey P.I., et al. Treatment of localized aggressive lymphomas with combination chemotherapy followed by involved-field radiation therapy. J. Clin. Oncol. 7:1989;1295-1302.
8. Kaiser U., Trümper L., Pfreundschuh M., Havemann K. Behandlung aggressiver Non-Hodgkin-Lymphome. Internist. 38:1997;135-142.
9. Armitage J.O. Treatment of non-Hodgkin's lymphoma. N. Engl. J. Med. 328:1992;1023-1030.
10. Fisher R.I., Gaynor E.R., Dahlberg S., et al. Comparison of CHOP vs m-BACOD vs ProMACE-CytaBOM vs MACOP-B in patients with intermediate- or high-grade non Hodgkin's lymphoma. N. Engl. J. Med. 328:1993;1002-1006.
11. Epelbaum R., Kuten A., Coachman N.M., et al. Stage I-II low-grade non-Hodgkin's lymphoma: prognostic factors and treatment results. Strahlenth Onkol. 168:1992;66-72.
12. Stuschke M., Hoederath A., Sack H., et al. Extended field and total central lymphatic radiotherapy in the treatment of early stage lymph node centroblastic-centrocytic lymphomas: results of a prospective multicenter study. Study Group NHL-fruhe Stadien. Cancer. 80:1997;2273-2284.
13. Longo D. What's the deal with follicular lymphoma? J. Clin. Oncol. 11:1993;202-208.
14. Hiddemann W. Non-Hodgkin's lymphomas - current status of therapy and future perspectives. Eur. J. Cancer. 31:1995;2141-2145.
15. Young R.C., Longo D.L., Glatstein E., Ihde D.C., Jaffe E.S., DeVita V.T. Jr. The treatment of indolent lymphomas: watchful waiting v. aggressive combined modality treatment. Semin. Hematol. 25:(Suppl. 2):1988;11-16.
16. Haioun C., Lepage E., Gisselbrecht C., et al. Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission. A study of 464 patients. J. Clin. Oncol. 12:1994;2543-2551.
17. Gisselbrecht C., Lepage E., Morel P., et al. Short and intensified treatment with autologous stem cell transplantation versus ACVB regimen in poor prognosis aggressive lymphoma. Prognostic factors of induction failure. Ann. Oncol. 7:(Suppl. 3):1996;18.
18. Bierman P.J., Vose J.M., Anderson J.R., Bishop M.R., Kessinger A., Armitage J.O. High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma. J. Clin. Oncol. 15:1997;445-450.
19. Solal-Celigny P., Lepage E., Brousse N., et al. Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. N. Engl. J. Med. 329:1993;1608-1614.
20. Decaudin D., Lepage E., Solal-Celigny P., et al. Low-grade follicular lymphoma: multivariate analysis of prognostic factors in 520 patients. Blood. 90:(Suppl. 1):1997;392a.
21. Unterhalt M., Herrmann R., Tiemann M., et al. Prednimustine, mitoxantrone (PmM) versus cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low grade non Hodgkin lymphoma. Leukemia. 10:1996;836-843.
22. Unterhalt M., Herrmann R., Koch P., et al. Prognostic determinants for long term outcome of low grade follicular lymphomas after cytoreductive, chemotherapy and interferon alpha maintenance. Results of the German Low Grade Lymphoma Study Group (GLSG). Blood. 90:(Suppl. 1):1997;1743a.
23. Hiddemann W., Unterhalt M., Herrmann R., et al. Mantle cell lymphomas have more widespread disease and a slower response to chemotherapy as compared to follicle center lymphomas. Result of a prospective comparative analysis of the German Low Grade Lymphoma Study Group. J. Clin. Oncol. 16:1998;1922-1930.
24. Anderson K.C., Bates M.P., Slaughenhoupt B.L., Pinkus G.S., Schlossmann S.F., Nadler L.M. Expression of human B-cell associated antigens on leukemias and lymphomas: a model of human B-cell differentiation. Blood. 63:1984;1424-1433.
25. Roitt I, Brostoff J, Make D. Immunology, 3rd edn. London, Gower Medical Publishing, 1991.
26. Taylor C., Linden H., Rubin M., et al. Phase I trial of mouse IgA anti-transferrin receptor monoclonal antibody 42/6 in patients with cancer. Proc. Am. Assoc. Cancer Res. 52:1994;377-384.
27. Vuist W.M.J., Levy R., Maloney D.G. Lymphoma regression induced by monoclonal anti-idiotypic antibodies correlates with their ability to induce Ig signal transduction and is not prevented by tumor expression of high levels of bcl-2 protein. Blood. 83:1994;899-906.
28. Maloney D.G., Smith B., Appelbaum F.R. The anti-tumor effect of monoclonal anti-CD20 antibody therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma cell lines. Blood. 83:1996;637a.
29. Jurcic J.G., Caron P.C., Scheinberg D.A. Monoclonal antibody therapy of leukemia and lymphoma. Adv. Pharm. 33:1995;287-314.
30. LoBuglio A.F., Mansoor N.S. Advances in monoclonal antibody therapy of cancer. Am. J. Med. Sci. 304:1992;214-224.
31. Grossbard M.L., Nadler L.M. Monoclonal antibody therapy for indolent lymphomas. Sem. Oncol. 5:(Suppl. 5):1993;118-135.
32. Vitetta E.S., Fulton R.J., May R.D., Till M., Uhr J.W.I. Redesigning nature's poisons to create antitumor reagents. Science. 238:1987;1098-1104.
33. Order S.E., Sleeper A.M., Stillwagon G.B., Klein J.L., Leichner P.K. Radiolabeled antibodies: results and potential in cancer therapy. Cancer Res. 50:1990;1011s-1013s.
34. Morrison S.L. Transfectomas provide novel chimeric antibodies. Science. 229:1986;379-393.
35. Jones P.T., Dear P.H., Foots J., Neuberber M.S., Winter G. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature. 321:1986;522-525.
36. LoBuglio A.F., Wheeler R.H., Trang J., et al. Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc. Natl. Acad. Sci. 86:1989;4220-4224.
37. Epenetos A.A., Snook D., Durbin H., Johnson P.M., Taylor-Papadimitriou J. Limitations of radiolabeled monoclonal antibodies for localization of human neoplasms. Cancer Res. 46:1986;3183-3191.
38. Strand S.E., Zanzonico P., Johnson T.K. Pharmacokinetic modelling. Med. Phys. 20:1993;515-527.
39. Juweid M., Neumann R., Paik C., et al. Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier. Cancer Res. 52:1992;5144-5153.
40. Skerra A. Bacterial expression of immunoglobulin fragments. Curr. Opin. Immunol. 5:1993;256-262.
41. Weiner G.J., Hillstrom J.R. Bispecific anti-idiotype/anti-CD3 antibody therapy of murine B cell lymphoma. J. Immunol. 147:1991;4035-4044.
42. Demanet C., Brissinck J., Leo O., Moser M., Thielemans K. Role of T-cell subsets in the bispecific antibody (anti-idiotype×anti-CD3) treatment of the BCL-1 lymphoma. Cancer Res. 54:1994;2973-2978.
43. Haagen I-A., Geerars A.J., de Lau W.B., et al. Killing of autologous B-lineage malignancy using CD3×CD19 bispecific monoclonal antibody in end stage leukemia and lymphoma. Blood. 84:1994;556-563.
44. Deo Y.M., Graziano R.F., Repp R., Van de Winkel J.G.J. Clinical significance of the IgG receptors and FcγR-directed immunotherapies. Immunol. Today. 18:1997;127-135.
45. Valerius T., Stockmeyer B., van Spriel A.B., et al. FcαRI (CD89) as a novel trigger molecule for bispecific antibodies. Blood. 90:1998;4485-4492.
46. Wooldridge J.E., Ballas Z., Krieg A.M., Weiner G.J. Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma. Blood. 89:1997;2994-2998.
47. Eiklid K., Olsnes S., Pihl A. Entry of lethal doses of abrin, ricin and modeccin in the cytosol of HeLa cells. Exp. Cell Res. 126:1980;321-326.
48. Roy D.C., Griffin J.D., Belvin M., Blattler W.A., Lambert J.M., Ritz J. Anti-My 9-blocked ricin: an immunotoxin for selective targeting of acute myeloid leukemia cells. Blood. 77:1991;2404-2412.
49. Brinkmann U., Pastan I. Recombinant immunotoxins: from basic research to cancer therapy. Methods. 8:1995;143-156.
50. Corcoran M.C., Eary J., Bernstein I., Press O.W. Radioimmunotherapy strategies for non-Hodgkin's lymphomas. Ann. Oncol. 8:(Suppl. 1):1997;S133-S138.
51. Anderson-Berg W.T., Squire R.A., Strand M. Specific radioimmunotherapy using 90-Y labeled antibody in erythroleukemic mice. Cancer Res. 47:1987;1905-1912.
52. 90Yttrium antiferritin - a new therapeutic radiolabeled antibody. Int. J. Radiat. Oncol. Biol. Phys. 12:1986;277-281.
53. 90Y-labeled monoclonal antibody 17-1A for treatment of human colon cancer xenografts. Int. J. Radiat. Oncol. Biol. Phys. 25:1993;629-638.
54. Kotz D. Alpha particle therapy poised to become new line of cancer treatment. J. Nucl. Med. 39:1998;17N-19N.
55. Vitetta E.S., Stone M., Amlot P., et al. Phase I immunotoxin trial in patients with B-cell lymphoma. Cancer Res. 51:1991;4052-4058.
56. Grossbard M.L., Lambert J.M., Goldmacher V.S., et al. Anti-B4-blocked ricin: a phase I trial of 7-day continuous infusion in patients with B-cell neoplasms. J. Clin. Oncol. 11:1993;726-737.
57. Stone M.J., Sausville E.A., Fay J.W., et al. A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma. Blood. 88:1996;1188-1197.
58. 486IL-2) in hematological malignancies expressing the IL-2 receptor. Blood. 79:1992;2547-2554.
59. Nichols J., Foss F., Kuzel T.M., et al. Interleukin-2 fusion protein: an investigational therapy for interleukin-2 receptor expressing malignancies. Eur. J. Cancer. 33:(Suppl. 1):1997;S34-S36.
60. 486IL-2, an IL-2-diphtheria fusion toxin. Blood. 78:(Suppl.):1991;175a.
61. 486IL-2 (OntakTM) for the treatment of mycoses fungoides (MF). Blood. 90:(Suppl. 1):1997;586a.
62. Frankel A.E., FitzGerald D., Siegall C., Press O.W. Advances in immunotoxin biology and therapy: a summary of the fourth international symposium on immunotoxins. Cancer Res. 56:1996;926-932.
63. Grossbard M.L., Gribben J.G., Freedman A.S., et al. Adjuvant immunotoxin therapy with anti B4-blocked ricin after autologous bone marrow transplantation for patients with B-cell non-Hodgkin's lymphoma. Blood. 81:1993;2263-2271.
64. Grossbard M.L., Niedzwiecki D., Nadler L.M., et al. Anti-B4-blocked ricin (Anti-B4-bR) adjuvant therapy post-autologous bone marrow transplant (ABMT)(CALGB 9254): a phase III intergroup study. Proc. Am. Soc. Clin. Oncol. 17:1998;3a.
65. Press O.W., Eary J.F., Badger C.C., et al. Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody. J. Clin. Oncol. 7:1989;1027-1038.
66. Kaminski M.S., Fig L.M., Zasadny K.R., et al. Imaging, dosimetry, and radioimmunotherapy with iodine-131-labeled anti-CD37 antibody in B-cell lymphoma. J. Clin. Oncol. 10:1992;1696-1711.
67. 131I] anti-B1 (anti-CD20) antibody. N. Engl. J. Med. 329:1993;459-465.
68. Kaminski M.S., Zasadny K.R., Francis I.R., et al. Iodine-131-anti B1 radioimmunotherapy for B-cell lymphoma. J. Clin. Oncol. 14:1996;1974-1981.
69. Kaminski M.S., Gribbin T., Estes J., et al. I-131 anti-B1 antibody for previously untreated follicular lymphoma (FL): clinical and molecular remissions. Proc. Am. Soc. Clin. Oncol. 17:1998;2a.
70. Press O.W., Eary J.F., Appelbaum F.R., et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N. Engl. J. Med. 329:1993;1219-1924.
71. 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet. 346:(8971):1995;336-340.
72. Czuczman M.S., Straus D.J., Divgi C.R., et al. Phase I dose-escalation trial of iodine 131-labeled monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma. J. Clin. Oncol. 11:1993;2021-2029.
73. Juweid M., Sharkey R.M., Markowitz A., et al. Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody. Cancer Res. 55:(23 Suppl.):1995;5899s-5907s.
74. Corcoran M.C., Eary J., Bernstein I., Press O.W. Radioimmunotherapy strategies for non-Hodgkin's lymphoma. Ann. Oncol. 8:(Suppl. 1):1997;133-138.
75. Press O.W., Appelbaum F., Ledbetter J.A., et al. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood. 69:1987;584-591.
76. Brown S.L., Miller R.A., Horning S.J., et al. Treatment of B-cell lymphomas with anti-idiotype antibodies alone and in combination with alpha interferon. Blood. 73:1989;651-661.
77. Maloney D.G., Brown S., Czerwinski D.K., et al. Monoclonal anti-idiotype antibody therapy of B-cell lymphoma: the addition of a short course of chemotherapy does not interfere with the antitumor effect nor prevent the emergence of idiotype-negative variant cells. Blood. 80:1992;1502-1510.
78. Maloney D.G., Liles T.M., Czerwinski D.K., et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood. 84:1994;2457-2466.
79. Maloney D.G., Grillo-Lopez A.J., Bodkin D., et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J. Clin. Oncol. 15:1997;3266-3274.
80. Maloney D.G., Grillo-Lopez A.J., White C.A., et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood. 90:1997;2188-2195.
81. Davis T., Levy R., White C.A., et al. Retreatments with RITUXAN™ (Rituximab, IDEC-C2B8) have significant efficacy, do not cause hama and are a viable minimally toxic alternative in relapsed or refractory non-Hodgkin's lymphoma (NHL). Blood. 90:(Suppl. 1):1997;509a.
82. Coiffier B., Ketterer N., Haioun C., et al. A multicenter, randomized phase II study of rituximab (chimeric anti-CD20 mAb) at two dosages in patients with relapsed or refractory intermediate or high-grade NHL (IHG-NHL) or in elderly patients in first-line therapy. Blood. 90:(Suppl. 1):1997;510a.
83. Link B.K., Grossbard M.L., Fisher R.I., et al. Phase II pilot study of the safety and efficacy of rituximab in combination with CHOP chemotherapy in patients with previously untreated intermediate- or high-grade NHL. Proc. Am. Soc. Clin. Oncol. 17:1998;3a.
84. Davis T., Maloney D., White C.A., et al. Combination immunotherapy of low grade or follicular (LG/F) non-Hodgkin's lymphoma (NHL) with Rituximab and alpha interferon: interim analysis. Proc. Am. Soc. Clin. Oncol. 17:1998;11a.
85. Kaminski M.S., Kitamura K., Maloney D.G., Campbell M.J., Levy R. Importance of antibody isotype in monoclonal anti-idiotype therapy of a murine B cell lymphoma. A study of hybridoma class switch variants. J. Immunol. 136:1986;1123-1130.
86. van Endert P.M., Heilig B., Hammerling G., Moldenhauer G. Monoclonal antibodies to idiotype inhibit in vitro growth of human B-cell lymphomas. Blood. 79:1992;129-137.
87. Caspar C.B., Levy S., Levy R. Idiotype vaccines for non-Hodgkin's lymphoma induce polyclonal immune response that cover mutated tumor idiotypes: comparison of different vaccine formulations. Blood. 90:1997;3699-3706.
88. Hsu F.J., Caspar C.B., Czerwinsky D., et al. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma - long-term results of a clinical trial. Blood. 89:1997;3129-3135.
89. Swisher E.M., Shawler D.L., Collins H.A., et al. Expression of shared idiotypes in chronic lymphocytic leukemia and small lymphocytic lymphoma. Blood. 77:1991;1977-1982.
90. Reff M.E., Carner K., Chambers K.S., et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 83:1994;435-445.
91. Maloney D.G., Smith B., Appelbaum F.R. The anti-tumor effect of monoclonal anti-CD20 antibody therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma cell lines. Blood. 88:(Suppl.):1996;637a.
92. Cabanillas F., Grillo-Lopez A.J., McLaughlin P., et al. Anti-CD20 antibody (MAB), IDEC-C2B8: clearance of bcl-2 t(14;18) positive cells from peripheral blood (PB) and bone marrow (BM) in patients (pts) with relapsed low-grade or follicular lymphoma (LG/F NHL). Blood. 88:(Suppl. 1):1996;91a.
93. Rogers J., Jackson J., Rosenberg J., et al. Clearance of bcl-2 (t14; 18) from peripheral blood (PB) and bone marrow (BM) in patients (pts) with relapsed low-grade or follicular (IWF: A-D) lymphoma (NHL) following single-agent therapy with the chimeric anti-CD20 antibody (MAB) IDEC-C2B8. Ann. Oncol. 7:1996;108a.
94. Marks C., Marks J.D. Phage libraries - a new route to clinically useful antibodies. N. Engl. J. Med. 335:1996;730-733.
95. Senter P.D., Saulnier M.G., Schreiber G.J., et al. Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate. Proc. Natl. Acad. Sci. 85:1988;4842-4846.
96. Bakina E., Wu Z., Rosenblum M., Farquhar D. Intensely cytotoxic anthracycline prodrugs: glucuronides. J. Med. Chem. 40:1997;4013-4018.
97. Saga T., Weinstein J.N., Jeong J.M., et al. Two-step targeting of experimental lung metastases with biotinylated antibody and streptavidin-biotin binding. Cancer Res. 54:1994;2160-2165.
98. Kobayashi H., Sakahara H., Hosono M., et al. Improved clearance of radiolabeled biotinylated monoclonal antibody following the infusion of avidin as a `chase' without decreased accumulation in the target tumor. J. Nucl. Med. 35:1994;1677-1684.
99. Paganelli G., Magnani P., Zito F., et al. Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients. Cancer Res. 51:1991;5960-5966.